Patient Summary We report a first bone biopsy study in metastatic prostate cancer in humans that searched for predictors of outcome of enzalutamide therapy. Benefit is linked to a pretreatment androgen-signaling signature.
European Urology, Volume 67 Issue 1, January 2015, Pages 53-60
Published online: 01 January 2015
Keywords: Enzalutamide, Castration-resistant prostate cancer, Predictors of outcome, Bone metastasis, Bone tumor microenvironment, Adaptive feedback mechanism, Androgen receptor, Primary resistance to enzalutamide, Androgen signaling inhibition, Tissue-based research